Home › Scleroderma › Florida › Miami
Scleroderma clinical trials in Miami, FL
4 studies for Scleroderma are looking for participants at sites in and around Miami (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
A Study of the Efficacy and Safety of Belimumab in Adults With Systemic Sclerosis Associated Interstitial Lung Disease
RecruitingPhase 2/3
- GSK Investigational Site, Miami
AlloNK®, an Allogeneic Non-genetically Modified, Cord Blood-derived NK Cell Therapy, in Combination With Rituximab, Studied in Relapsing Forms of B-cell Dependent Rheumatologic Diseases.
RecruitingPhase 2
- Artiva Investigational Site Miami, Miami
A Phase 1 Study of FT819 in B-cell Mediated Autoimmune Disease
RecruitingPhase 1
- Nicklaus Children's Hospital, Miami
Study to Evaluate the Efficacy, Safety, and Tolerability of Efzofitimod in Patients With Systemic Sclerosis (SSc)-Related Interstitial Lung Disease (ILD) (SSc-ILD)
RecruitingPhase 2
- aTyr Investigative Site, Miami
About Scleroderma
Scleroderma is an autoimmune disease that causes inflammation and thickening in the skin and other areas of the body. The exact cause of scleroderma is unknown.
More about Scleroderma on MedlinePlus
Scleroderma trials in other cities
- New York City, NY11 studies
- Ann Arbor, MI10 studies
- Chicago, IL10 studies
- Houston, TX9 studies
- Boston, MA7 studies
- Durham, NC7 studies
- Los Angeles, CA7 studies
- New Orleans, LA6 studies
- Baltimore, MD6 studies
- Philadelphia, PA6 studies
- Dallas, TX5 studies
- Pittsburgh, PA5 studies
Other studies in Miami
- Breast Cancer42 studies
- Cancer (all types)36 studies
- Non-Small Cell Lung Cancer31 studies
- Prostate Cancer27 studies
- Obesity27 studies
- Acute Myeloid Leukemia24 studies
- Metastatic Cancer24 studies
- Ovarian Cancer23 studies
- Overweight23 studies
- Multiple Myeloma21 studies
- Ulcerative Colitis21 studies
- Alzheimer's Disease20 studies
From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.